Talia Puzantian, PharmD, BCPP
Clinical psychopharmacology consultant in private practice, Los Angeles, CA. www.taliapuzantian.comDr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
In January of this year, the FDA approved the stimulant lisdexamfetamine (Vyvanse) as the first drug with an indication for binge eating disorder (BED). Patients are hearing the buzz and may be asking you to prescribe it, but you may have some questions first.
James Lock, PhD, MD
Professor of psychiatry and pediatrics at Stanford University School of Medicine
Dr. Lock has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dr. Lock outlines a treatment method for anorexia nervosa that helps family members better understand the disorder and enlists their help in providing a home environment based on successful inpatient services for weight restoration.
Michael Posternak, MD
Psychiatrist in private practice in Boston, MA
Patients with schizophrenia often stop taking their medications, so long-acting injectable antipsychotics (LAIs) are potentially good ways to make sure these patients have some medication in their systems over the long term.
Steve Balt, MD, MS
Board Member, The Carlat Report. In private practice in the San Francisco Bay area.
Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.
Choosing the “right” treatment for a given patient involves a large number of factors, including personal preference—both the clinician’s and the patient’s. Is there a better way?
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Assurex Health recently sent me an email inviting me to dine at Legal Seafood to learn about “Clinical Applications of Psychiatric Pharmacogenetics.” I didn’t go, but increasingly I am hearing from colleagues about their experiences at these dinner programs: “What do you think about this GeneSight test? The data looked pretty impressive at this dinner.”
James Coyne, PhD
Clinical health psychologist, Emeritus Professor of Psychiatry, University of Pennsylvania School of Medicine
Professor of Health Psychology, University of Groningen, the Netherlands
Dr. Coyne has disclosed that he has no relevant financial or other interest in any commercial companies pertaining to this educational activity.
Get advice on how to evaluate the methodology of biomarker studies in an interview with James Coyne, PhD, clinical health psychologist, professor emeritus of in the psychiatry with University of Pennsylvania and professor of health psychology, University of Groningen, the Netherlands.
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
There are plenty of ways that we use technology in psychiatric practice these days—including e-prescribing, electronic health records, referring patients to websites for psychoeducation, etc. But when was the last time you referred a patient to their computer for psychotherapy? Well, it may be time to consider it.